Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?

[1]  J. Jiménez-Moleón,et al.  Psychosocial Impairment as a Possible Cause of Sexual Dysfunction among Young Men with Mild Androgenetic Alopecia: A Cross-sectional Crowdsourcing Web-based Study. , 2016, Acta dermatovenerologica Croatica : ADC.

[2]  V. Mysore,et al.  Guidelines on the use of finasteride in androgenetic alopecia , 2016, Indian journal of dermatology, venereology and leprology.

[3]  L. Garcia-Segura,et al.  Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know? , 2015, Reviews in Endocrine and Metabolic Disorders.

[4]  M. Etminan,et al.  Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low‐Dose Finasteride: A Pharmacovigilance Study , 2015, Pharmacotherapy.

[5]  Nicolas Perez-Mora,et al.  Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men. , 2015, Skinmed.

[6]  Chieh-Hsi Wu,et al.  A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia , 2015, Clinical endocrinology.

[7]  B. Walker,et al.  5α-Reductase Type 1 Deficiency or Inhibition Predisposes to Insulin Resistance, Hepatic Steatosis, and Liver Fibrosis in Rodents , 2014, Diabetes.

[8]  A. Hoes,et al.  Long-term use of 5α-reductase inhibitors and the risk of male breast cancer , 2014, Cancer Causes & Control.

[9]  Katherine A. Hughes,et al.  5α-Reductase Type 1 Modulates Insulin Sensitivity in Men , 2014, The Journal of clinical endocrinology and metabolism.

[10]  K. Katsuoka,et al.  A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. , 2014, Journal of the American Academy of Dermatology.

[11]  M. Etminan,et al.  Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. , 2013, The Journal of urology.

[12]  Ian M Thompson,et al.  Long-term survival of participants in the prostate cancer prevention trial. , 2013, The New England journal of medicine.

[13]  H. Laydner,et al.  Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis. , 2013, Journal of the American Academy of Dermatology.

[14]  F. Gil-Bea,et al.  Mineralocorticoid Receptor Activation Induces Insulin Resistance Through c‐Jun N‐terminal kinases in Response to Chronic Corticosterone: Cognitive Implications , 2013, Journal of neuroendocrinology.

[15]  A. Te,et al.  A 5‐year retrospective analysis of 5α‐reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride , 2012, International journal of clinical practice.

[16]  M. Irwig.  Persistent sexual side effects of finasteride: could they be permanent? , 2012, The journal of sexual medicine.

[17]  W. Hellstrom,et al.  Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. , 2012, The journal of sexual medicine.

[18]  F. Marrosu,et al.  Finasteride attenuates pathological gambling in patients with Parkinson disease. , 2012, Journal of clinical psychopharmacology.

[19]  S. Arias-Santiago,et al.  Androgenetic alopecia as an early marker of benign prostatic hyperplasia. , 2012, Journal of the American Academy of Dermatology.

[20]  K. Sjögren,et al.  Reduced Bone Mass and Muscle Strength in Male 5α-Reductase Type 1 Inactivated Mice , 2011, PloS one.

[21]  Gordon Guyatt,et al.  Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. , 2010, Archives of dermatology.

[22]  Salvador Arias-Santiago,et al.  Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. , 2010, Journal of the American Academy of Dermatology.

[23]  J. Fernández-Crehuet,et al.  Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old , 2008, The British journal of dermatology.

[24]  J. Waldstreicher,et al.  Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. , 2003, Urology.

[25]  R. Grimalt,et al.  Delusional hyperhidrosis as a risk for medical overtreatment: a case of botulinophilia. , 2001 .

[26]  M. Hill,et al.  Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride. , 2010, Endocrine regulations.

[27]  P. Habibollahi,et al.  BMC Clinical Pharmacology BioMed Central Research article , 2006 .